Portugal now part of MRA with FDA
Recommendation
14/15 October 2026
Vienna, Austria
Quality Oversight of Pharmaceutical Contract Manufacturing Organisations
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
After a positive assessment, the US Food and Drug Administration (FDA) has approved Portugal to be fully covered by the current EU-FDA Mutual Recognition Agreement (MRA) of GMP inspections of human manufacturers.
The total number of countries accepted by the FDA is now 15: Croatia, France, Italy, Malta, Spain, Sweden, United Kingdom, Czech Republic, Greece, Austria, Hungary, Romania, Lithuania, Ireland and Portugal.
Other EU member states will be added as their evaluation is completed by the US. According to a previous EMA press release, "Plans for the agreement to be operational in all EU Member States by 15 July 2019 are on track."
Source: EMA Press Release entitled "Portugal to also benefit from EU-US mutual recognition agreement for inspections".
Related GMP News
16.09.2026How GMP Non-Compliance can stop a Marketing Authorisation Application
10.09.2026FDA Warning Letter: Inadequate Warehouse Controls and Lot Traceability
09.09.2026Specified Microorganisms and More - FDA Warning Letter
02.09.2026Deficiencies in Staffing, Monitoring and Aseptic Techniques – Warning Letter to a European Company
19.08.2026Poor Hygiene and Environmental Conditions - FDA Warning Letter